Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.

Bromopride appears to be safe and effective for use in pregnancy.

Indications

Bromopride is indicated in the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV); gastroesophageal reflux disease (GERD/GORD); and as preparation for endoscopy and radiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications, hiccups and gastrointestinal adverse effects of radiation therapy.

Adverse effects

Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as metoclopramide, may increase prolactin levels.

Chemistry

Bromopride is a substituted benzamide, closely related to metoclopramide. It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.

Availability

Bromopride is not available in the United States or the United Kingdom. It is marketed in Brazil by Sanofi-Synthélabo under the trade name Digesan and as a generic drug.

References